<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Guzman ML</submitter><funding>NCI NIH HHS</funding><pagination>4436-44</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2234782</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>110(13)</volume><pubmed_abstract>Leukemia is thought to arise from malignant stem cells, which have been described for acute and chronic myeloid leukemia (AML and CML) and for acute lymphoblastic leukemia (ALL). Leukemia stem cells (LSCs) are relatively resistant to current chemotherapy and likely contribute to disease relapse and progression. Consequently, the identification of drugs that can efficiently eradicate LSCs is an important priority. In the present study, we investigated the antileukemia activity of the compound TDZD-8. Analysis of primary AML, blast crisis CML (bcCML), ALL, and chronic lymphoblastic leukemia (CLL) specimens showed rapid induction of cell death upon treatment with TDZD-8. In addition, for myeloid leukemias, cytotoxicity was observed for phenotypically primitive cells, in vitro colony-forming p</pubmed_abstract><journal>Blood</journal><pubmed_title>Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8).</pubmed_title><pmcid>PMC2234782</pmcid><funding_grant_id>R01 CA090446</funding_grant_id><funding_grant_id>R01 CA90446</funding_grant_id><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Jordan CT</pubmed_authors><pubmed_authors>Liesveld JL</pubmed_authors><pubmed_authors>Hebert J</pubmed_authors><pubmed_authors>Young F</pubmed_authors><pubmed_authors>Guzman ML</pubmed_authors><pubmed_authors>Rossi RM</pubmed_authors><pubmed_authors>Corbett CA</pubmed_authors><pubmed_authors>Bushnell T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8).</name><description>Leukemia is thought to arise from malignant stem cells, which have been described for acute and chronic myeloid leukemia (AML and CML) and for acute lymphoblastic leukemia (ALL). Leukemia stem cells (LSCs) are relatively resistant to current chemotherapy and likely contribute to disease relapse and progression. Consequently, the identification of drugs that can efficiently eradicate LSCs is an important priority. In the present study, we investigated the antileukemia activity of the compound TDZD-8. Analysis of primary AML, blast crisis CML (bcCML), ALL, and chronic lymphoblastic leukemia (CLL) specimens showed rapid induction of cell death upon treatment with TDZD-8. In addition, for myeloid leukemias, cytotoxicity was observed for phenotypically primitive cells, in vitro colony-forming p</description><dates><release>2007-01-01T00:00:00Z</release><publication>2007 Dec</publication><modification>2026-03-16T16:46:52.217Z</modification><creation>2025-06-01T01:34:35.005Z</creation></dates><accession>S-EPMC2234782</accession><cross_references><pubmed>17785584</pubmed><doi>10.1182/blood-2007-05-088815</doi></cross_references></HashMap>